Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal has one working extract — disproportionate reporting signal workbook — after an AdCom briefing document that overstates subgroup findings. If disproportionate reporting signal workbook cannot support the 505(b)(2) bridge is, the only defensible Pharma & Life Sciences output is hold.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. The population in disproportionate reporting signal workbook is the one an AdCom briefing document that overstates subgroup findings named, so Proceed under protocol follows for this CMC and Development Pathways file. 2. The population in disproportionate reporting signal workbook is adjacent only to an AdCom briefing document that overstates subgroup findings; Pause the pathway is the honest Pharma & Life Sciences call. 3. A safety team sitting on a new disproportionate signal already contained an AdCom briefing document that overstates subgroup findings before disproportionate reporting signal workbook arrived; no new CMC and Development Pathways path. 4. Provenance on disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 3. Check whether disproportionate reporting signal workbook supports the labeled claim regulatory-affairs lead would keep. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read disproportionate reporting signal workbook against an AdCom briefing document that overstates subgroup findings and write the one fact that would move the 505(b)(2) bridge is for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for regulatory-affairs lead in a safety team sitting on a new disproportionate signal.